Squarepoint’s Protagonist Therapeutics PTGX Stock Holding History

Squarepoint’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,000	Closed	-$725K	–	4952
2025 Q1	$725K	Buy	+15,000	New	+$629K	﹤0.01%	2940

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's PTGX Position: Q4 2024 in Review

Squarepoint sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 18,566 shares — an estimated $835K sold.

Squarepoint first reported a position in PTGX in Q1 2018 and held it in 18 quarters. The position peaked at $3.41M in Q2 2020. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

Squarepoint reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
Squarepoint sold 18,566 Protagonist Therapeutics shares in Q4 2024, an estimated $835K.
Squarepoint first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 18 quarters.
Squarepoint's Protagonist Therapeutics position peaked at $3.41M in Q2 2020.
241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.